10:57 AM
 | 
Jan 09, 2019
 |  BC Extra  |  Company News

China’s Junshi prices domestic anti-PD-1 mAb at deep discount

Shanghai Junshi Biosciences Co. Ltd. (HKSE:1877) priced its domestically developed anti-PD-1 mAb Tuoyi toripalimab at a deep discount compared with the China price of Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK), which has the same mechanism.

Junshi set Tuoyi’s price at RMB7,200 ($1,050.91) per 240 mg. On a per-milligram basis, the price is an 83% discount compared with Keytruda's RMB17,918 ($2,615.31) per 100 mg. Both drugs are approved in China to treat melanoma (see "China Approves First Anti-PD-1 for Melanoma").

Last month, Tuoyi became the first domestic anti-PD-1 antibody to be approved by China's National Medical Products Administration (NMPA). The mAb is in clinical testing in China for various cancers (see “China Approves Junshi’s Tuoyi, First Domestic Anti-PD-1 mAb”).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD